Tudor Investment Corp
ADAP

Tudor Investment Corp’s Adaptimmune Therapeutics ADAP Stock Holding History

Tudor Investment Corp’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,232
Closed -$26K – 2263
2022
Q2 		$26K Hold
15,232
– – ﹤0.01% 2002
2022
Q1 		$31K Sell
15,232
-670
-4% -$1.81K ﹤0.01% 1886
2021
Q4 		$60K Sell
15,902
-102
-0.6% -$464 ﹤0.01% 2260
2021
Q3 		$83K Buy
+16,004
New +$71.8K ﹤0.01% 2367

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tudor Investment Corp's ADAP Position: Q3 2022 in Review

Tudor Investment Corp sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 15,232 shares — an estimated $26K sold.

Tudor Investment Corp first reported a position in ADAP in Q3 2021 and held it in 4 quarters. The position peaked at $83K in Q3 2021. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

  • Tudor Investment Corp reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Tudor Investment Corp sold 15,232 Adaptimmune Therapeutics shares in Q3 2022, an estimated $26K.
  • Tudor Investment Corp first reported a position in Adaptimmune Therapeutics in Q3 2021 and held it in 4 quarters.
  • Tudor Investment Corp's Adaptimmune Therapeutics position peaked at $83K in Q3 2021.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Tudor Investment Corp's 13F filing for Q3 2022, filed 14 Nov 2022.